Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
136 hedge funds and large institutions have $352M invested in Esperion Therapeutics in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 42 reducing their positions, and 18 closing their positions.
417% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $2.78M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
46% more capital invested
Capital invested by funds: $241M → $352M (+$111M)
33% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 18
5.14% more ownership
Funds ownership: 82.66% → 87.8% (+5.1%)
3% more funds holding
Funds holding: 132 → 136 (+4)
0% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$11.6M |
| 2 |
Millennium Management
New York
|
+$8.27M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.03M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$4.79M |
| 5 |
BlackRock
New York
|
+$3.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$7.56M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$6.18M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$3.41M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$2.27M |
| 5 |
MAM
Monaco Asset Management
Monaco
|
-$1.4M |
ESPR Hedge Fund Activity: Q2 2022 in Review
136 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q2 2022, worth a combined $352M — up 46% from $241M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ESPR positions and 18 closed out — a net gain of 6 holders — while 42 added to existing stakes and 42 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $11.6M. The largest seller was Altium Capital Management, cutting an estimated $7.56M.
- 136 institutional investors held Esperion Therapeutics (ESPR) as of Q2 2022, up from 132 in Q1 2022.
- Funds reported $352M of Esperion Therapeutics stock for Q2 2022, up 46% quarter-over-quarter.
- 24 funds opened new Esperion Therapeutics positions in Q2 2022 and 18 closed out, a net change of +6 holders.
- The largest Esperion Therapeutics buyer in Q2 2022 was Ikarian Capital, an estimated $11.6M added.
- The largest Esperion Therapeutics seller in Q2 2022 was Altium Capital Management, an estimated $7.56M sold.
Based on aggregated 13F filings for Q2 2022.